Lv1
30 积分 2021-02-19 加入
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
11小时前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
1天前
已完结
Recent advances in the development of EGFR degraders: PROTACs and LYTACs
15天前
已完结
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
1个月前
已完结
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
1个月前
已完结
Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity
2个月前
已完结
GPR35: from enigma to therapeutic target
2个月前
已完结
Immunopathogenesis of IBD: current state of the art
4个月前
已完结
Recent advances in structural studies of 14-3-3 protein complexes
5个月前
已完结
皖公网安备34019202002308
